主要投资者出售了Teva制药公司的股份,但该公司仍然比预期的收益高。 Major investors sold off Teva Pharmaceutical shares, but the company still beat earnings expectations.

在第四季度,Teva制药工业公司在主要投资人法律和一般集团Plc和APG资产管理公司N.V.的销售中占有相当大的份额。 Teva Pharmaceutical Industries saw significant share sales by major investors Legal & General Group Plc and APG Asset Management N.V. in the fourth quarter. 尽管销售量如此,但Teva报告说,每股收入略有减少,并预测该年的EPS为2.5 EPS。 Despite these sales, Teva reported a slight beat on earnings per share and forecasts a 2.5 EPS for the year. 该公司开发非专利药品和特种药品,市场上限为152.2亿美元,负净差为9.91%。 The company, which develops generic and specialty medicines, has a market cap of $15.22 billion and a negative net margin of 9.91%.